 Shamir Mehta |  Keith Fox |  Petr Widimsky |  Gerrit Veen |
OASIS 5 & 6: Fondaparinux Anticoagulation: Benefit on Mortality, Events and Bleeding in Acute Coronary Syndromes and ST-Elevation Myocardial Infarction
REFERENCE: Abstract 1745
Shamir Mehta, McMaster University, Hamilton, Canada
Results in over 30 000 patients with acute coronary syndromes or ST elevation myocardial infarction in the OASIS 5 and OASIS 6 studies experienced better mortality, fewer events and less bleeding if their anticoagulation was with the factor 10a inhibitor fondaparinux. Shamir Mehta of McMaster University in Hamilton, Canada, presented results to the Barcelona cardiology congress of superior outcomes compared with other anticoagulation regimens.
Early Invasive Therapy for Acute Coronary Syndromes: ICTUS Trial, FRISC II Study, Prague II and OASIS
REFERENCE: Abstracts 1739, 1741, 1743 and 1746
Keith Fox, Royal Infirmary, Edinburgh
Early invasive therapy for acute coronary syndromes was under the microscope at the conference in Barcelona. Keith Fox of Edinburgh University discussed the FRISC II study from Sweden which reported superiority for an early invasive strategy, and after his talk Peter Goodwin asked him about this and about the ICTUS trial from the Netherlands which failed to show an advantage.
Prague II Study Shows “Transport to PCI” Better for Acute Myocardial Infarction Than Thrombolysis
REFERENCE: Abstract 1741
Petr Widimsky, Charles University, Prague
Even if patients with myocardial infarction have to be transported to a referral centre some hours away from their home they are still likely to benefit more from primary percutaneous intervention rather than thrombolyis. This is the conclusion after five years of follow up in the Prague II study reported at the Barcelona conference by Petr Widimsky of Charles University in Prague. Peter Goodwin asked him about the results.
The VIAMI Study: Myocardial Viability Must Guide Angioplasty After Thrombolysis
REFERENCE: Abstract 3417
Gerrit Veen, VU University, Amsterdam
A check should be made for myocardial viability before going ahead with angioplasty after thrombolyis, according to the findings of the VIAMI (Viability-guided Angioplasty after Acute Myocardial Infarction study) from the Netherlands. Because thrombolyis is still the mainstay of treatment for MI around the world, the study looked at candidates for intervention after lysis and found that some patients do better with conservative therapy. Sarah Maxwell talked with Gerit Veen of VU University in Amsterdam.
